

Client: Chi Med
Source: AFX News
Date: 29 February 2008
Page: N/A
Circulation: N/A

Citigate
Dewe Rogerson

Hutchison China starts patient enrolment for anti-inflammatory drug phase IIB

LONDON (Thomson Financial) - Hutchison China Meditech Ltd said it has started patient enrolment in phase IIB ulcerative colitis clinical trial of HMPL-004, its anti-inflammatory drug candidate.

The global clinical trial programme has been designed to further test the drug candidate's efficacy, assess its safety profile in a broader patient population and to evaluate different dose regimens in preparation for the Phase III trials with HMPL-004.

The company is expected to complete patient recruitment by third quarter 2009.

TFN.newsdesk@thomson.com
ukn/ejp

COPYRIGHT

Copyright Thomson Financial News Limited 2007. All rights reserved.

The copying, republication or redistribution of Thomson Financial News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Financial News.